---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-116808"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:54:35.831992+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics Q3 net loss $30.7M; cash $395.3M; CNTY-101 trial imminent

## Summary
- Net loss $30.7M for Q3 2022 vs $26.0M in Q3 2021; R&D expenses rose to $25.9M.
- Cash, cash equivalents, and investments totaled $395.3M at Sep 30, 2022; runway into 2025.
- Full-year 2022 GAAP operating expense guidance lowered to $140M-$145M (incl. $10-$15M stock comp).
- Phase 1 ELiPSE-1 trial of CNTY-101 in B-cell malignancies to begin imminently after FDA clearance.
- Appointed Daphne Quimi and Timothy Walbert to Board; SITC data and R&D Day on Nov 11.

## SEC filing metadata
- accession: 0001104659-22-116808
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465922116808/0001104659-22-116808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465922116808/tm2230058d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-116808
- JSON: https://secwatch.observer/filing/0001104659-22-116808.json
- Plain text: https://secwatch.observer/filing/0001104659-22-116808.txt

## Key facts
- Earnings Releases
  Century Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue Collaboration revenue was $2.2 million, net income Net loss was $30.7 million. Guidance lowered.
  - Period: the third quarter ended September 30, 2022
  - Revenue: Collaboration revenue was $2.2 million
  - Net income: Net loss was $30.7 million
  - Guidance: lowered
  - Result: reported results
  source text: of $118.5 million) compared to net cash used in operations of $64.7 million for the nine months ended September 30, 2021. ● Collaboration Revenue: Collaboration revenue was $2.2 million for the three months ended September 30, 2022, generated through the Company’s collaboration, option and license agreement with BMS. ● Research and Development (R&D) expenses
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465922116808/0001104659-22-116808-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.